Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: billkirn who wrote (830)	6/15/1997 11:56:00 AM
From: John Metcalf	of 6136

Sure. DMP-266 (DuPont-Merck) and PMEA (GS-840, Gilead) are non-nucleoside reverse transcriptase inhibitors (NNRTI's). PMEA is being tested against hepatitis B as well as HIV infection. 141W94 (VX-478) is a new protease inhibitor from Vertex, being developed with Glaxo-Wellcome -- A pivotal study should be complete early in 1998. 1592U89 is a new "nuke" (nucleoside reverse transcriptase inhibitor) from Glaxo. There are many new products in development, which will receive accelerated regulatory consideration due to the seriousness of HIV infection and the emergence of resistance to existing treatments. NNRTI's are being tested with PI's (viz., Crixivan + DMP-366). I've seen no information on how they will be used in treatment. Possibly, NNRTI's will replace nukes. Possibly, they'll be added to cocktails. Glaxo would like to see 141 + 1592 + AZT/3TC. Merck would like to see Crixivan + DMP-366. Agouron has indicated that double PI therapy will be the wave of the future. Further studies will provide indicators on these questions, but the decisions will be made by doctors and patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next